Ampersand Biomedicines

Flagship’s Ampersand Bio Adds $65M to Solve One of the Top Challenges in Medicine

Ampersand Biomedicines’ map of all tissue in the human body reveals “addresses,” identifying markers on disease targets that are not found on healthy tissue. The company aims to improve the targeting of biologic drugs in order to reduce on-target, off-tissue toxicity.

By Frank Vinluan

Flagship Startup Emerges With $50M to Send Drugs to the Right Biologic Address

Ampersand Biomedicines emerged from stealth with technology for site-specific drug delivery that avoids toxic effects throughout the body. The Flagship Pioneering-founded startup is backed by $50 million in financing.

By Frank Vinluan

A Data-Driven Guide to Patient Access Success

A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.

By Relatient

How PDPM Optimization Improves Facility Financial Performance

Transitioning to PDPM models significantly shifted the healthcare industry. By replacing the RUG system, healthcare providers cut waste and more accurately reflect the care each patient received.

By Medrina

Artificial Intelligence

Why Your Patients Are Leaving and How to Stop It

Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.

By Bryan Sequeira, Director, Product Management Greenway Health